Sun Pharma plans additional investment in Assam unit
Assam government has informed that Sun Pharma will invest an additional Rs. 200-crore at its plant in the state to augment operations. Assam Chief Minister Mr. Sarbananda Sonowal recently inaugurated a new production line at Sun Pharma’s facility in Palashbari.
“The company has already invested Rs. 700-crore in this manufacturing facility in the state and another Rs. 200-crore is going to be invested,” an official release from the Chief Minister’s Office said. The company has invested Rs. 120-crore to set up this new production line, which will boost the capacity to manufacture liquid vials, injectables, eye drops and tablets among others, the release said.
Speaking on the occasion, Sun Pharma’s MD Mr. Dilip Shanghvi said that the plant is expected to become one of the largest facilities in next few years in the company’s network to manufacture sterile products.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Retatrutide/Tirzepatide/Cagri/Ghk-Cu 99% White Raw Power High Quality 2381089-83-2 Weight Loss Peptide
$178.7/G FOB
2026-07-17
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
McKinsey Pays to Close a Purdue Liability Chapter
Recommend Reading
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
Expected Short-term Peak Season Surge, This Week's Polyester Chip Market in China Shows High-level Fluctuations
-
Firm Costs and Weak Demand Lead to High-Level Fluctuations in the Chinese PTA Market
-
Surge by 4,000 CNY/ton! Is the melamine market in China showing signs of peaking?
-
Positive Factors Drive March Butanol Price Increase by Over 40%
-
Bullish Factors Remain, April Adipic Acid Prices in China Expected to Rise